(0.01%) 5 207.00 points
(0.07%) 39 025 points
(-0.12%) 18 175 points
(0.38%) $78.78
(-1.96%) $2.15
(-0.33%) $2 323.40
(-0.49%) $27.48
(-0.11%) $963.85
(0.09%) $0.929
(0.29%) $10.86
(0.18%) $0.797
(-0.37%) $91.00
@ $6.07
Issued: 13 Feb 2024 @ 15:46
Return: -12.36%
Previous signal: Feb 13 - 09:30
Previous signal:
Return: -2.10 %
Live Chart Being Loaded With Signals
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases...
Stats | |
---|---|
Today's Volume | 237 763 |
Average Volume | 638 508 |
Market Cap | 512.77M |
EPS | $-0.490 ( 2024-05-02 ) |
Next earnings date | ( $-0.510 ) 2024-06-12 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.41 |
ATR14 | $0.00700 (0.13%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-30 | Polaris Venture Management Co. Vi, L.l.c. | Sell | 500 000 | Common Stock |
2024-04-30 | Polaris Venture Management Co. Vi, L.l.c. | Buy | 98 533 | Common Stock |
2024-04-30 | Polaris Venture Management Co. Vi, L.l.c. | Sell | 98 533 | Common Stock |
2024-03-19 | Altmeyer Mark | Buy | 41 250 | Common Stock |
2024-03-19 | Altmeyer Mark | Buy | 19 420 | Stock Option (right to buy) |
INSIDER POWER |
---|
-25.37 |
Last 100 transactions |
Buy: 2 784 515 | Sell: 4 159 752 |
Volume Correlation
Alector Inc Correlation
10 Most Positive Correlations | |
---|---|
INGN | 0.946 |
UEIC | 0.946 |
SPTN | 0.942 |
NKTR | 0.94 |
SSP | 0.938 |
TUEM | 0.931 |
AADI | 0.931 |
MQ | 0.929 |
GBNH | 0.928 |
BAND | 0.927 |
10 Most Negative Correlations | |
---|---|
XLRN | -0.935 |
ALR | -0.917 |
ORTX | -0.917 |
FLMN | -0.917 |
CPTA | -0.916 |
TYHT | -0.911 |
HILS | -0.91 |
MYRG | -0.909 |
INOD | -0.909 |
RESN | -0.906 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Alector Inc Correlation - Currency/Commodity
Alector Inc Financials
Annual | 2023 |
Revenue: | $97.06M |
Gross Profit: | $88.21M (90.88 %) |
EPS: | $-1.560 |
FY | 2023 |
Revenue: | $97.06M |
Gross Profit: | $88.21M (90.88 %) |
EPS: | $-1.560 |
FY | 2022 |
Revenue: | $133.62M |
Gross Profit: | $125.15M (93.66 %) |
EPS: | $-1.620 |
FY | 2021 |
Revenue: | $207.09M |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-0.467 |
Financial Reports:
No articles found.
Alector Inc
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators